105 related articles for article (PubMed ID: 24378498)
1. Second malignant neoplasms and cardiovascular disease following radiotherapy.
Travis LB; Ng AK; Allan JM; Pui CH; Kennedy AR; Xu XG; Purdy JA; Applegate K; Yahalom J; Constine LS; Gilbert ES; Boice JD
Health Phys; 2014 Feb; 106(2):229-46. PubMed ID: 24378498
[TBL] [Abstract][Full Text] [Related]
2. Second malignant neoplasms and cardiovascular disease following radiotherapy.
Travis LB; Ng AK; Allan JM; Pui CH; Kennedy AR; Xu XG; Purdy JA; Applegate K; Yahalom J; Constine LS; Gilbert ES; Boice JD
J Natl Cancer Inst; 2012 Mar; 104(5):357-70. PubMed ID: 22312134
[TBL] [Abstract][Full Text] [Related]
3. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer.
van den Belt-Dusebout AW; de Wit R; Gietema JA; Horenblas S; Louwman MW; Ribot JG; Hoekstra HJ; Ouwens GM; Aleman BM; van Leeuwen FE
J Clin Oncol; 2007 Oct; 25(28):4370-8. PubMed ID: 17906202
[TBL] [Abstract][Full Text] [Related]
4. Second malignant neoplasms: assessment and strategies for risk reduction.
Wood ME; Vogel V; Ng A; Foxhall L; Goodwin P; Travis LB
J Clin Oncol; 2012 Oct; 30(30):3734-45. PubMed ID: 23008293
[TBL] [Abstract][Full Text] [Related]
5. Cancer and non-cancer effects in Japanese atomic bomb survivors.
Little MP
J Radiol Prot; 2009 Jun; 29(2A):A43-59. PubMed ID: 19454804
[TBL] [Abstract][Full Text] [Related]
6. Late complications of therapy of Hodgkin's disease: prevention and management.
Ng AK; Mauch PM
Curr Hematol Rep; 2004 Jan; 3(1):27-33. PubMed ID: 14695846
[TBL] [Abstract][Full Text] [Related]
7. Cancer survivorship--genetic susceptibility and second primary cancers: research strategies and recommendations.
Travis LB; Rabkin CS; Brown LM; Allan JM; Alter BP; Ambrosone CB; Begg CB; Caporaso N; Chanock S; DeMichele A; Figg WD; Gospodarowicz MK; Hall EJ; Hisada M; Inskip P; Kleinerman R; Little JB; Malkin D; Ng AK; Offit K; Pui CH; Robison LL; Rothman N; Shields PG; Strong L; Taniguchi T; Tucker MA; Greene MH
J Natl Cancer Inst; 2006 Jan; 98(1):15-25. PubMed ID: 16391368
[TBL] [Abstract][Full Text] [Related]
8. Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1.
Lunsford LD; Flickinger JC; Larson D
Oncologist; 1997; 2(1):59-61. PubMed ID: 10388030
[TBL] [Abstract][Full Text] [Related]
9. Long-term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatment.
van Leeuwen FE; Ng AK
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):323-330. PubMed ID: 27913498
[TBL] [Abstract][Full Text] [Related]
10. Genetic variation as a modifier of association between therapeutic exposure and subsequent malignant neoplasms in cancer survivors.
Bhatia S
Cancer; 2015 Mar; 121(5):648-63. PubMed ID: 25355167
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic radiation and the potential risk of second malignancies.
Kamran SC; Berrington de Gonzalez A; Ng A; Haas-Kogan D; Viswanathan AN
Cancer; 2016 Jun; 122(12):1809-21. PubMed ID: 26950597
[TBL] [Abstract][Full Text] [Related]
12. Dose-effect relationships for adverse events after cranial radiation therapy in long-term childhood cancer survivors.
van Dijk IW; Cardous-Ubbink MC; van der Pal HJ; Heinen RC; van Leeuwen FE; Oldenburger F; van Os RM; Ronckers CM; Schouten-van Meeteren AY; Caron HN; Koning CC; Kremer LC
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):768-75. PubMed ID: 22954771
[TBL] [Abstract][Full Text] [Related]
13. [Long-term complications following treatment of testicular cancer and Hodgkin lymphoma].
van den Belt-Dusebout AW; Aleman BM; Gietema JA; de Wit R; van 't Veer MB; Lugtenburg PJ; Krol AD; van Leeuwen FE
Ned Tijdschr Geneeskd; 2010; 154(45):A2229. PubMed ID: 21118593
[TBL] [Abstract][Full Text] [Related]
14. Roles of radiation dose and chemotherapy in the etiology of stomach cancer as a second malignancy.
van den Belt-Dusebout AW; Aleman BM; Besseling G; de Bruin ML; Hauptmann M; van 't Veer MB; de Wit R; Ribot JG; Noordijk EM; Kerst JM; Gietema JA; van Leeuwen FE
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1420-9. PubMed ID: 19931732
[TBL] [Abstract][Full Text] [Related]
15. Long-term mortality from second malignant neoplasms in 5-year survivors of solid childhood tumors: temporal pattern of risk according to type of treatment.
Tukenova M; Diallo I; Hawkins M; Guibout C; Quiniou E; Pacquement H; Dhermain F; Shamsaldin A; Oberlin O; de Vathaire F
Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):707-15. PubMed ID: 20200431
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis of second cancer risk after radiotherapy among childhood cancer survivors.
Doi K; Mieno MN; Shimada Y; Yonehara H; Yoshinaga S
Radiat Prot Dosimetry; 2011 Jul; 146(1-3):263-7. PubMed ID: 21561937
[TBL] [Abstract][Full Text] [Related]
17. Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up.
Brusamolino E; Baio A; Orlandi E; Arcaini L; Passamonti F; Griva V; Casagrande W; Pascutto C; Franchini P; Lazzarino M
Clin Cancer Res; 2006 Nov; 12(21):6487-93. PubMed ID: 17085663
[TBL] [Abstract][Full Text] [Related]
18. Can we reduce the incidence of second primary malignancies occurring after radiotherapy? A critical review.
Tubiana M
Radiother Oncol; 2009 Apr; 91(1):4-15; discussion 1-3. PubMed ID: 19201045
[TBL] [Abstract][Full Text] [Related]
19. Second malignant neoplasms in testicular cancer survivors.
Fung C; Fossa SD; Beard CJ; Travis LB
J Natl Compr Canc Netw; 2012 Apr; 10(4):545-56. PubMed ID: 22491051
[TBL] [Abstract][Full Text] [Related]
20. Genetic susceptibility to radiogenic cancer in humans.
Allan JM
Health Phys; 2008 Nov; 95(5):677-86. PubMed ID: 18849702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
